
USD
+$0.00
(+0.00%
)At Close (As of Dec 15, 2025)
$33.04M
Market Cap
-
P/E Ratio
-0.55
EPS
$6.20
52 Week High
$1.35
52 Week Low
HEALTHCARE
Sector
| Field | Value (EUR) |
|---|---|
| Gross Profit | - |
| Total Revenue | $0 |
| Cost Of Revenue | - |
| Costof Goods And Services Sold | - |
| Operating Income | -$9.8M |
| Selling General And Administrative | $5M |
| Research And Development | $4.8M |
| Operating Expenses | $9.8M |
| Investment Income Net | - |
| Net Interest Income | $81K |
| Interest Income | $81K |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $45K |
| Income Before Tax | -$8.9M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$8.9M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$9.8M |
| Ebitda | -$9.7M |
| Net Income | -$8.9M |
| Field | Value (EUR) |
|---|---|
| Total Assets | $15M |
| Total Current Assets | $14M |
| Cash And Cash Equivalents At Carrying Value | $4.6M |
| Cash And Short Term Investments | $4.6M |
| Inventory | - |
| Current Net Receivables | $1.4M |
| Total Non Current Assets | $351K |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $88K |
| Intangible Assets Excluding Goodwill | $88K |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $8.1M |
| Other Current Assets | $365K |
| Other Non Current Assets | - |
| Total Liabilities | $2.3M |
| Total Current Liabilities | $2.1M |
| Current Accounts Payable | $318K |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $13K |
| Total Non Current Liabilities | $229K |
| Capital Lease Obligations | - |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $15K |
| Other Current Liabilities | $1.8M |
| Other Non Current Liabilities | $1.2K |
| Total Shareholder Equity | $12M |
| Treasury Stock | - |
| Retained Earnings | -$56M |
| Common Stock | $68M |
| Common Stock Shares Outstanding | $18M |
| Field | Value (EUR) |
|---|---|
| Gross Profit | - |
| Total Revenue | $0 |
| Cost Of Revenue | - |
| Costof Goods And Services Sold | - |
| Operating Income | -$9.8M |
| Selling General And Administrative | $5M |
| Research And Development | $4.8M |
| Operating Expenses | $9.8M |
| Investment Income Net | - |
| Net Interest Income | $81K |
| Interest Income | $81K |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $45K |
| Income Before Tax | -$8.9M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$8.9M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$9.8M |
| Ebitda | -$9.7M |
| Net Income | -$8.9M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Genenta Science SpA (GNTA) is an innovative clinical-stage biotechnology company headquartered in Milan, Italy, specializing in hematopoietic stem cell gene therapies for solid tumors. Leveraging cutting-edge genetic engineering technologies, Genenta is dedicated to pioneering transformative therapies that aim to redefine cancer treatment paradigms. With a promising pipeline and strategic collaborations, the company stands out in the oncology landscape, presenting a compelling investment opportunity for institutional investors looking for exposure to groundbreaking advancements in the biotechnology sector.